News & Updates
Filter by Specialty:
Show Multimedia Only

Povorcitinib passes efficacy, safety tests in phase II trial for extensive vitiligo
22 Oct 2025
byStephen Padilla
Treatment with the Janus kinase (JAK) 1 inhibitor povorcitinib results in significant repigmentation of the body and face in adult patients with extensive nonsegmental vitiligo (NSV), with an acceptable safety profile, through 52 weeks, reports a phase II study.
![[Infographics] Expanding roles of semaglutide in CKM syndrome](https://cdn.mspsit.mims.com/images/articles/hk-non-076md00-a37499f5-94bf-481b-b399-4a1163c81066-square.png)







